Skip to content
Home » Report on Amyotrophic Lateral Sclerosis (ALS) in the United States

Report on Amyotrophic Lateral Sclerosis (ALS) in the United States


Amyotrophic Lateral Sclerosis (ALS), often known as Lou Gehrig’s disease, stands as a formidable adversary in the realm of progressive neurodegenerative diseases. It relentlessly attacks the nerve cells in both the brain and spinal cord, leading to muscle weakness, disability, and eventually, death. This report delves into the prevalence of ALS within the United States, with a keen focus on specific demographics such as veterans and athletes. It explores the enigmatic nature of its causes, scrutinizes the demographic distribution, evaluates the current therapeutic landscape, and shines a light on the hopeful paths being carved by new research.

Prevalence of ALS

In the United States, an estimated 20,000 individuals grapple with ALS at any given moment, with about 5,000 new cases diagnosed annually, according to the ALS Association. However, the disease does not burden all demographics equally:

  • Veterans: Research underscores a troubling trend among military veterans who are about twice as likely to develop ALS compared to the general population. This increased risk spans across all service branches and eras of military engagement, underscoring the need for further investigation into the unique environmental or occupational exposures faced by this group.

  • Athletes: The connection between ALS and athletes, particularly those in high-impact sports, is a growing area of concern. Repeated head injuries have been implicated as a potential risk factor, though comprehensive statistics remain elusive, signaling a pressing need for more focused research in this domain.

Possible Environmental Causes

The search for ALS’s etiology has cast a wide net over environmental toxins such as heavy metals, pesticides, and industrial chemicals. Despite the circumstantial evidence suggesting a link, the definitive cause-and-effect relationship remains just beyond our grasp, necessitating ongoing research efforts.

Male-to-Female Ratios

ALS exhibits a slight predilection towards males, with a male-to-female ratio of approximately 1.5:1. This discrepancy is not static but shifts with age, diminishing in older age groups, which suggests underlying biological or environmental factors that may influence disease susceptibility or progression differently across genders.

Current Therapies

  • Riluzole and Edaravone: The FDA has greenlit two drugs for ALS—Riluzole, which can extend survival by a few months, and Edaravone, believed to decelerate disease progression in certain patients.

  • Supportive Care: Beyond pharmacological interventions, ALS management heavily relies on a multidisciplinary approach. Teams comprising physical therapists, respiratory specialists, and nutritionists work synergistically to palliate symptoms and enhance the quality of life for those afflicted.

New Research and Possible Medications

  • Gene Therapy: The frontier of gene therapy offers a glimmer of hope for genetic forms of ALS, with early trials showing promise in slowing the relentless march of the disease.

  • Stem Cell Therapy: Meanwhile, stem cell research endeavors to unlock new potentials in treating ALS by repairing or replacing the neurons ravaged by the disease, though its efficacy is still under investigation.

Current Death Rate

The prognosis for ALS patients is grim, with the majority succumbing to respiratory failure within 3 to 5 years from symptom onset. Only about 20% survive beyond five years, highlighting the urgent need for more effective treatments.


ALS continues to be a devastating and enigmatic challenge. Its disproportionate impact on veterans and athletes underscores the imperative for specialized research efforts. Meanwhile, advancements in gene and stem cell therapies hold the promise of future breakthroughs. The journey towards understanding ALS and devising effective treatments is fraught with hurdles, yet driven by resilience, hope, and the relentless pursuit of knowledge, we move closer to a future where ALS can be conquered.

Sophia’s Mission is an advocate for those living on the autistic spectrum, individuals with disabilities, veterans, the poor, hungry, homeless, and those suffering from diseases. Founded in 2019 as a 501(c)3 organization, it emphasizes creating employment opportunities in the audio, radio, and media sectors, thereby fostering an environment of diversity and inclusivity. Through partnerships like NEWHD Media, it operates platforms to provide unique opportunities and support for those who face challenges in traditional employment settings.

"Breaking Barriers: Empowering Individuals with Disabilities and Veterans to Reach Their Full Potential"
Verified by MonsterInsights